Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBITDA (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBITDA for 12 consecutive years, with -$64.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 6.8% to -$64.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$256.0 million, a 25.61% increase, with the full-year FY2025 number at -$256.0 million, up 25.61% from a year prior.
  • EBITDA was -$64.7 million for Q4 2025 at ImmunityBio, down from -$55.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$55.6 million in Q3 2025 to a low of -$111.6 million in Q1 2023.
  • A 5-year average of -$82.2 million and a median of -$82.6 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 324.71% in 2021, then soared 32.32% in 2025.
  • ImmunityBio's EBITDA stood at -$79.3 million in 2021, then fell by 7.1% to -$84.9 million in 2022, then fell by 0.58% to -$85.4 million in 2023, then grew by 18.72% to -$69.4 million in 2024, then increased by 6.8% to -$64.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EBITDA are -$64.7 million (Q4 2025), -$55.6 million (Q3 2025), and -$71.3 million (Q2 2025).